Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis

摘要

A previous systematic review published by our research team showed that a number of studies have explored de-escalation of bone-targeted agents. An updated systematic review/meta-analysis was performed to assess if de-escalation should be considered standard of care in patients with breast cancer. There appears to be no difference in skeletal-related events or pain with de-escalated therapy.De-escalation of bone-targeted agents, such as bisphosphonates and denosumab, from 4- to 12-weekly dosing is an increasingly used strategy in patients with bone metastases from breast cancer. It is unclear whether there is sufficient evidence to support de-escalation as a standard of care.